Health · Medical Research · 5 hrs ago
Nearly 40% of nAMD patients stopped anti-VEGF treatment
A review of a large clinical database found that poor adherence to anti-VEGF therapy remains a major limitation in treating neovascular age-related macular degeneration, or nAMD.
Almost 40% of patients stopped treatment, the review found.
nAMD is the condition discussed in the review, and anti-VEGF therapy is an existing treatment for it.
The findings point to difficulty staying on treatment as an important issue in care.
The source does not say why patients stopped or describe a change to treatment.
It also does not say what happens next.
A review of a large clinical database found that almost 40% of patients with neovascular age-related macular degeneration stopped anti-VEGF treatment.
Poor adherence remains a major limitation of existing therapies for the condition.
The review examined real-world treatment choices for age-related macular degeneration.
- Who
- Patients with neovascular age-related macular degeneration.
- What
- A review found that almost 40% stopped anti-VEGF treatment.
- When
- Not stated.
- Where
- Not stated.
- Why
- The sources do not state why patients stopped treatment.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Patients who stopped treatment
- Almost 40%
- Condition
- Neovascular age-related macular degeneration (nAMD)
- Treatment
- Anti-VEGF therapy
- Evidence source
- Review of a large clinical database